Date: 2013-09-03
Type of information:
phase: 1
Announcement: first administration to human
Company: Imaxio (France)
Product: MVA85A-IMX313
Action mechanism: Imaxio\'s proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used. IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates, and is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.
Disease: tuberculosis
Therapeutic area: Infectious diseases
Country: UK
Trial details: This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313. The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University. (NCT01879163)
Latest
news: